|
|
|
|
Oxidative Damage to Nucleic Acids in Severe Emphysema
* Gaetan Deslee, MD; Jason C.Woods, PhD; Carla Moore; Susan H. Conradi, PhD; David S. Gierada, MD; Lucy Liu; G. Alexander Patterson, MD; Tracy L. Adair-Kirk, PhD; Michael J. Holtzman, MD and Richard A. Pierce, PhD From the...
|
|
|
King Of Pop's Reported Diagnosis Sheds Light On Relatively Unknown Disease
In light of reports that Michael Jackson is suffering from a rare respiratory condition caused by Alpha 1-Antitrypsin Deficiency, Jeffrey Teckman, M.D., associate professor of pediatrics, biochemistry and molecular biology...
|
|
|
Health Highlights: Dec. 23, 2008
Here are some of the latest health and medical news developments, compiled by editors of HealthDay: FDA Says Diet Coke Plus Claims Violate Regulations The U.S.has warned Coca-Cola Co., the world's largest soft-drink maker, that its claims...
|
|
|
GTC Closes $15 Million Convertible Debt Financing from LFB
- GTC Biotherapeutics, Inc.('GTC', Nasdaq: GTCB) has closed on the agreement with LFB Biotechnologies for a $15 million financing in which GTC issued convertible debt and warrants to purchase shares of GTCB common stock on the terms...
|
|
|
King of Pop's Reported Diagnosis Sheds Light on Relatively Unknown Disease
Newswise In light of reports that Michael Jackson is suffering from a rare respiratory condition caused by Alpha 1-Antitrypsin Deficiency, Jeffrey Teckman, M.D., associate professor of pediatrics, biochemistry and molecular...
|
|
|
Michael Jackson's Reported Lung Disease
22, 2008 -- Pop superstar Michael Jackson may need a lung transplant because of a genetic condition called alpha-1 antitrypsin deficiency, according to media reports.Those reports cite British newspapers that quote...
|
|
|
GTC Closes $15 Million Convertible Debt Financing from LFB
- GTC Biotherapeutics, Inc.('GTC', Nasdaq: GTCB) has closed on the agreement with LFB Biotechnologies for a $15 million financing in which GTC issued convertible debt and warrants to purchase shares of GTCB common stock on the terms...
|
|
|
GTC Closes $15 Million Convertible Debt Financing from LFB
GTC Biotherapeutics, Inc.('GTC', Nasdaq: GTCB) has closed on the agreement with LFB Biotechnologies for a $15 million financing in which GTC issued convertible debt and warrants to purchase shares of GTCB common stock on the terms...
|
|
|
Health Highlights: Dec. 23, 2008
Michael Jackson's Publicist Says Illness Rumors False Singer Michael Jackson's publicist says reports that the 'King of Pop' is seriously ill 'are a total fabrication.' 'Mr.Jackson is in fine health, and finalizing negotiations with a...
National Womens Health Information Center:
Dec 23 2008 7:38PM
Matching: alpha 1 antitrypsin
|
Find similar documents
|
|
|
|
Michael Jackson Has Deadly Genetic Disease?
Michael Jackson has a potentially deadly genetic disease, it has been claimed.The 50-year-old pop superstar - who has previously been photographed looking frail in a wheelchair - is said to be battling inherited condition A1AD (alpha...
|
|
|
Kamada Completes Enrollment In Its Phase II Bronchiectasis Trial With Inhaled AAT
Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced recently that it has completed patient enrollment in its Phase II clinical trial...
|
|
|
Health Highlights: Dec. 22, 2008
Michael Jackson Said to Need Lung Transplant Michael Jackson, the self-proclaimed King of Pop, needs a lung transplant because he's suffering from a rare respiratory condition, according to the author of a new Jackson biography.Author Ian...
National Womens Health Information Center:
Dec 22 2008 7:29PM
Matching: alpha 1 antitrypsin
|
Find similar documents
|
|
|
|
Kamada completes enrollment in Phase II bronchiectasis trial
A total of 21 patients with bronchiectasis were enrolled and randomized into this, double-blind, placebo controlled Phase II study.The purpose of the trial is to investigate safety and efficacy of inhaled Alpha-1 ...
|
|
|
Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
- Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that it has completed patient enrollment in its Phase II clinical trial...
|
|
|
Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that it has completed patient enrollment in its Phase II clinical trial evaluating...
|
|
|
Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
Chief Executive Officer of Kamada, David Tsur, said, 'We are very pleased with the progress of this study and look forward to its upcoming completion.We believe that Kamada's AAT delivered by PARI's eFlow has the potential to become a...
|
|
|
Do You Have Genetic COPD?
/PRNewswire/ -- To everyone around her, Melissa Biggs appeared to have it all -- a thriving acting career, a successful clothing line that was attracting international attention, and an adoring daughter.What people didn't know was that...
|
|
|
GTC Biotherapeutics to Webcast Corporate Presentation at the Rodman & Renshaw 10th Annual Healthcare Conferenc
FRAMINGHAM, Mass., Nov.5, 2008--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (GTC, Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTCs Chairman and CEO, is scheduled to present on Tuesday, November 11, 2008 at 10:20 a.m. during...
|
|
|
Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
Title: United States Patent: 7,435,869 Inventors: Velander; William H.(Blacksburg, VA), Drohan; William N. (Springfield, VA), Lubon; Henryk (Rockville, MD), Johnson; John L. (Blacksburg, VA) Assignee: Virgina Tech. Intellectual...
|
|
|
Kamada completes final analysis of Phase III AAT deficiency trial
The trial, conducted in accordance with FDA requirements, was a controlled, randomized, double-blind, partial cross-over study that compared Kamada's intravenous alpha-1 antitrypsin (AAT) with a comparator product.
|
|
|
AAV vectors for gene delivery to the lung
Title: United States Patent: 7,427,396 Inventors: Arbetman; Alejandra E.(San Francisco, CA), Lochrie; Michael A. (Hayward, CA) Assignee: Genzyme Corporation (Framingham, MA) Appl. No.: 11/143,866 Filed: June 2, 2005 Methods of making...
|
